The most common side effects were: Nausea Vomiting Diarrhea Constipation Fatigue Abdominal discomfort Early satiety Injection site reactions Increased heart rate in the first 24 weeks, but that returned to normal after 24 weeks
MOTS-c has attracted considerable scientific interest because of its role in metabolism, and early human studies have begun, but there is currently insufficient evidence to support its use for obesity or osteoporosis, Dr
Get the Injury, Joint & Recovery Blueprint *Educational only No protocols Written by clinicians* When to Use BPC-157 + TB-500 This blend is ideal for a range of patients and scenarios, including: Athletes looking to recover from training faster Post-surgical patients needing accelerated healing Individuals with tendinopathy , ligament sprains , or joint instability Chronic pain sufferers seeking regenerative alternatives Patients with gut inflammation or leaky gut (BPC-157 has GI-healing properties) People with connective tissue disorders or injury-prone joints Individuals experiencing inflammatory joint conditions (such as arthritis) Expected Results While every patient responds differently, many experience: Reduced pain and inflammation within 12 weeks Enhanced range of motion and tissue resilience Accelerated recovery time from injuries or surgeries Improved mobility and flexibility Reduced gut permeability and inflammation (via BPC-157) Peak results are typically seen 48 weeks into therapy, depending on severity and dosing
Your primary physician should offer their own obesity counseling
Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER
Certain people are more prone to having low B12 levels than others
